| # | Title | Journal | Year | Citations |
|---|
| 1 | A genome-wide association study identifies colorectal cancer susceptibility loci on chromosomes 10p14 and 8q23.3 | Nature Genetics | 2008 | 514 |
| 2 | Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for CYP2C19 and Voriconazole Therapy | Clinical Pharmacology and Therapeutics | 2017 | 266 |
| 3 | Cytochrome P450 Gene Polymorphism and Cancer | Current Drug Metabolism | 2004 | 257 |
| 4 | Prevalence of CYP2D6 gene duplication and its repercussion on the oxidative phenotype in a white population* | Clinical Pharmacology and Therapeutics | 1995 | 178 |
| 5 | Characteristics of subjects experiencing hypersensitivity to non-steroidal anti-inflammatory drugs: patterns of response | Clinical and Experimental Allergy | 2011 | 173 |
| 6 | Identification and characterisation of novel polymorphisms in theCYP2Alocus: implications for nicotine metabolism | FEBS Letters | 1999 | 158 |
| 7 | Interethnic and Intraethnic Variability of CYP2C8 and CYP2C9 Polymorphisms in Healthy Individuals | Molecular Diagnosis and Therapy | 2006 | 156 |
| 8 | Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6 genotype and use of ondansetron and tropisetron | Clinical Pharmacology and Therapeutics | 2017 | 151 |
| 9 | Pharmacogenetic allele nomenclature: International workgroup recommendations for test result reporting | Clinical Pharmacology and Therapeutics | 2016 | 146 |
| 10 | Polymorphisms of Human N-Acetyltransferases and Cancer Risk | Current Drug Metabolism | 2008 | 124 |
| 11 | Evaluation of Caffeine as an In Vivo Probe for CYP1A2 Using Measurements in Plasma, Saliva, and Urine | Therapeutic Drug Monitoring | 2000 | 121 |
| 12 | Genetic predisposition to acute gastrointestinal bleeding after NSAIDs use | British Journal of Pharmacology | 2004 | 117 |
| 13 | Comparative in vitro and in vivo inhibition of cytochrome P450 CYP1A2, CYP2D6, and CYP3A by H -receptor antagonists | Clinical Pharmacology and Therapeutics | 1999 | 114 |
| 14 | The effect of the cytochrome P450 CYP2C8 polymorphism on the disposition of (R)-ibuprofen enantiomer in healthy subjects | British Journal of Clinical Pharmacology | 2005 | 109 |
| 15 | CYP1A2 activity, gender and smoking, as variables influencing the toxicity of caffeine | British Journal of Clinical Pharmacology | 1996 | 93 |
| 16 | Genetically based impairment in CYP2C8- and CYP2C9-dependent NSAID metabolism as a risk factor for gastrointestinal bleeding: Is a combination of pharmacogenomics and metabolomics required to improve personalized medicine? | Expert Opinion on Drug Metabolism and Toxicology | 2009 | 92 |
| 17 | Clinical pharmacogenomic testing of KRAS, BRAF and EGFRmutations by high resolution melting analysis and ultra-deep pyrosequencing | BMC Cancer | 2011 | 83 |
| 18 | High frequency of mutations related to impaired CYP2C9 metabolism in a Caucasian population. | European Journal of Clinical Pharmacology | 2001 | 79 |
| 19 | Polymorphic Drug Metabolism in Anaesthesia | Current Drug Metabolism | 2009 | 78 |
| 20 | Genetics of restless legs syndrome: An update | Sleep Medicine Reviews | 2018 | 78 |
| 21 | Loss-of-Function Mutations in HPSE2 Cause the Autosomal Recessive Urofacial Syndrome | American Journal of Human Genetics | 2010 | 75 |
| 22 | Identification and prevalence study of 17 allelic variants of the human NAT2 gene in a white population | Pharmacogenetics and Genomics | 1996 | 71 |
| 23 | Caffeine metabolism in a healthy Spanish population: N-Acetylator phenotype and oxidation pathways | Clinical Pharmacology and Therapeutics | 1994 | 68 |
| 24 | Cerebrospinal fluid biochemical studies in patients with Parkinson's disease: toward a potential search for biomarkers for this disease | Frontiers in Cellular Neuroscience | 2014 | 68 |
| 25 | Debrisoquine oxidation phenotype during neuroleptic monotherapy | European Journal of Clinical Pharmacology | 1991 | 66 |
| 26 | Association between the oxidative polymorphism and early onset of Parkinson's disease* | Clinical Pharmacology and Therapeutics | 1995 | 65 |
| 27 | Interaction of CYP2C8 and CYP2C9 genotypes modifies the risk for nonsteroidal anti-inflammatory drugs-related acute gastrointestinal bleeding | Pharmacogenetics and Genomics | 2008 | 64 |
| 28 | Lung cancer and mutations at the polymorphic NAT2 gene locus | Pharmacogenetics and Genomics | 1995 | 62 |
| 29 | Leflunomide-induced acute hepatitis | Digestive and Liver Disease | 2004 | 62 |
| 30 | Unraveling Ambiguous NAT2 Genotyping Data | Clinical Chemistry | 2008 | 62 |
| 31 | Refinement of the basis and impact of common 11q23.1 variation to the risk of developing colorectal cancer | Human Molecular Genetics | 2008 | 61 |
| 32 | CYP2D6 genes and risk of liver cancer | Lancet, The | 1995 | 59 |
| 33 | Increased risk for hepatocellular carcinoma in NAT2-slow acetylators and CYP2D6-rapid metabolizers | Pharmacogenetics and Genomics | 1996 | 59 |
| 34 | Pharmacogenomics in Aspirin Intolerance | Current Drug Metabolism | 2009 | 58 |
| 35 | Expression of paclitaxel-inactivating CYP3A activity in human colorectal cancer: implications for drug therapy | British Journal of Cancer | 2002 | 57 |
| 36 | Vitamin D3 Receptor (VDR) Gene rs2228570 (Fok1) and rs731236 (Taq1) Variants Are Not Associated with the Risk for Multiple Sclerosis: Results of a New Study and a Meta-Analysis | PLoS ONE | 2013 | 57 |
| 37 | Polymorphisms of the glutathione S-transferases mu-1 (GSTM1) and theta-1 (GSTT1) and the risk of advanced alcoholic liver disease | Scandinavian Journal of Gastroenterology | 2005 | 56 |
| 38 | Debrisoquin oxidation polymorphism in a Spanish population | Clinical Pharmacology and Therapeutics | 1988 | 54 |
| 39 | Adenosine triphosphate-binding cassette B1 (ABCB1) (multidrug resistance 1) G2677T/A gene polymorphism is associated with high risk of lung cancer | Cancer | 2006 | 54 |
| 40 | Polymorphisms of histamine‐metabolizing enzymes and clinical manifestations of asthma and allergic rhinitis | Clinical and Experimental Allergy | 2007 | 54 |
| 41 | Expression in human prostate of drug- and carcinogen-metabolizing enzymes: association with prostate cancer risk | British Journal of Cancer | 1998 | 53 |
| 42 | Determination of fluoxetine and norfluoxetine in human plasma by high-performance liquid chromatography with ultraviolet detection in psychiatric patients | Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences | 2003 | 52 |
| 43 | Debrisoquin oxidation genotype and susceptibility to lung cancer | Clinical Pharmacology and Therapeutics | 1994 | 51 |
| 44 | Polymorphism of the <i>TLR4</i> Gene Reduces the Risk of Hepatitis C Virus-Induced Hepatocellular Carcinoma | Oncology | 2012 | 50 |
| 45 | Polymorphisms in Methotrexate Pathways: What Is Clinically Relevant, What Is Not, and What Is Promising | Current Drug Metabolism | 2009 | 50 |
| 46 | Genetic basis for differences in debrisoquin polymorphism between a spanish and other white populations | Clinical Pharmacology and Therapeutics | 1994 | 49 |
| 47 | Diamine Oxidase rs10156191 and rs2052129 Variants Are Associated With the Risk for Migraine | Headache | 2015 | 49 |
| 48 | Effect of Thioridazine Dosage on the Debrisoquine Hydroxylation Phenotype in Psychiatric Patients With Different CYP2D6 Genotypes | Therapeutic Drug Monitoring | 2001 | 48 |
| 49 | Assessment of nonsteroidal anti-inflammatory drug-induced hepatotoxicity | Expert Opinion on Drug Metabolism and Toxicology | 2011 | 48 |
| 50 | Association of CYP2C9 genotypes leading to high enzyme activity and colorectal cancer risk | Carcinogenesis | 2001 | 47 |
